Lymphoma Clinical Trials

Showing 781-800 of 3,379 trials

Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies

NCT04732845

The purpose of this study is to determine if it is possible to treat relapsed or refractory lymphoid malignancies (Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia) with a new type of T cell-based immunotherapy (therapy that uses the immune system to treat the cancer).

Non Hodgkin LymphomaAcute Lymphoblastic LeukemiaChronic Lymphocytic Leukemia

Benjamin Tomlinson18 participantsStarted Apr 2021

Cleveland, Ohio, United States

Active Not RecruitingPhase 2

A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma

NCT04416451

This study will help researchers understand how effective the combination of venetoclax and rituximab is in treating MZL in people who have not received a previous treatment for their cancer.

Marginal Zone Lymphoma

Memorial Sloan Kettering Cancer Center6 participantsStarted May 2021

Duarte, California, United States • Basking Ridge, New Jersey, United States • Middletown, New Jersey, United States +5 more locations

Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies

A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma

Related Searches

TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers

Clinical Study of CEP+Dasatinib + Azacytidine in First-line Treatment of. Angioimmunoblastoma Foresight

Expectations and Priorities of Elderly Patients for a First Medical Treatment for Cancer

Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus PREVENAR20) in Adult Patients Treated for a Lymphoma

A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

A First-in-human Study to Assess OT-C001 (Amplified/Activated Allogenic Natural Killer Cells) in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

Efficacy of 68Ga-Pentixafor PET/MR in Detecting Non-Hodgkin Lymphoma and Multiple Myeloma Lesions

1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation

Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL

Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas

Assessing An Oral JAK1 Inhibitor, Golidocitinib, in Patients Who Have Newly Diagnosed Peripheral T-Cell Lymphoma (JACKPOT23)

Primary Mediastinal Large B-cell Lymphoma With CNS Involvement

DOLPHIN-VIVO: Diagnosis Of LymPHoma IN Vivo (In Vivo Phase)

Registry of Older Patients With Cancer

A Phase 1 Study of TRS005 in Patients With R/R CD20-positive B-NHL.

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

Obinutuzumab in Combination With GDP Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma